Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia
Open Access
- 12 July 2008
- Vol. 113 (6), 1370-1378
- https://doi.org/10.1002/cncr.23691
Abstract
BACKGROUND. It is unknown whether patients with nonleukemic myeloid sarcoma (MS) and those with acute myeloid leukemia (AML) have similar responses to anti‐AML treatment. In the current study, the authors addressed this question by matching MS patients with analogous AML patients and comparing their clinical outcomes. METHODS. Twenty‐three consecutive patients with MS and 1720 consecutive patients with AML were identified who presented at The University of Texas M. D. Anderson Cancer Center from 1990 to 2004. All AML patients and 16 MS patients received cytarabine plus idarubicin or fludarabine as induction remission therapy. Treated MS patients and AML patients were matched according to cytogenetics, age, Zubrod performance status, and time of treatment. Event‐free survival (EFS) and overall survival (OS) were compared using Kaplan‐Meier analyses. RESULTS. Complete response rates were 69% in patients with MS and 57% in patients with AML (P = .45). The respective 2‐year EFS and OS rates were 32% and 18% (P = .08) and 43% and 29% (P = .11). Matches were identified for 14 MS patients who were paired repeatedly with 91 AML patients to produce 94 matches (3 AML patients were matched twice). EFS was longer in 56 MS pair mates, shorter in 26 pair mates, and similar in 12 pair mates (P = .01; Fisher exact test). OS analyses yielded similar results. CONCLUSIONS. Anti‐AML therapy was highly effective in patients with nonleukemic MS. The results from this study emphasize the need to treat patients who have nonleukemic MS with AML‐type therapy. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 18 references indexed in Scilit:
- Recurrent Gefitinib-induced Interstitial Lung DiseaseInternal Medicine, 2008
- Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patientsLeukemia, 2006
- Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)Blood, 2006
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) TabletsThe Oncologist, 2003
- Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapyLeukemia, 2003
- Severe acute interstitial pneumonia and gefitinibThe Lancet, 2003
- Comparison in treatments of nonleukemic granulocytic sarcomaCancer, 2002
- Acute lung injury as a possible adverse drug reaction related to gefitinib.European Respiratory Journal, 2002
- The Immunophenotyping of Extramedullary Myeloid Cell Tumors in Paraffin-Embedded Tissue SectionsThe American Journal of Surgical Pathology, 1988